Bildkälla: Stockfoto

Pila Pharma Q3 2022: Funding Remains a Hurdle - Redeye

Redeye leaves its view on Pila Pharma following its report for the third quarter of 2022. We comment on yesterday's rights issue, the content in the report, and lower our Base case.

Redeye leaves its view on Pila Pharma following its report for the third quarter of 2022. We comment on yesterday's rights issue, the content in the report, and lower our Base case.
Börsvärldens nyhetsbrev
ANNONSER